Table 1. Cell lines used for this study.
| Cell line | Genotype | Lymphoma-specific antigen | Rejection in wild type B6 |
| 291PC | λ-hu-MYC tg | huMYC | 0% |
| 291GFP | λ-hu-MYC tg | huMYC/GFP | 60% |
| 291OVA | λ-hu-MYC tg | huMYC/GFP/OVA | 75% |
| 83OVA | λ-hu-MYC; tg Act-OVA tg | OVA | 100% |
| 9PC | STAT1−/− λ-hu-MYC tg | huMYC | 30% |
| 9OVA | STAT1−/−; λ-hu-MYC tg | huMYC/GFP/OVA | 82% |
| 50PC | IFN-γ-R−/−; λ -hu-MYC tg | huMYC | 0% |
| 50OVA | IFN-γ-R−/−; λ -hu-MYC tg | huMYC/GFP/OVA | 93% |
Overview of genotype potential foreign antigens and rejection of lymphoma cell lines used in this study. Numbers are given as % of rejection after s.c. injection of 1×105 lymphoma cells from cell lines indicated into recipient wild type C57BL/6 mice.